Table 2.
Procedural characteristics of first FMT.
| Number of patients – no. | 256 |
| Antibiotic inductiona – no. (%) | 199 (77.7) |
| Metronidazole only | 3 (1.2) |
| Vancomycin only | 154 (60.2) |
| Fidaxomicin only | 15 (5.9) |
| Rifaximin only | 6 (2.3) |
| Combination | 21 (8.2) |
| None | 46 (18.0) |
| Unknown | 12 (4.7) |
| Antimotility agent – no. (%) | 28 (10.9) |
| Proton pump inhibitor – no. (%) | 10 (3.9) |
| Frozen preparations – no. (%) | 68 (26.6) |
| Bowel lavage – no. (%) | 171 (66.8) |
| Type of application – no. (%) | |
| Gastric | 7 (2.7) |
| direct endoscopic | 7 (2.7) |
| Duodenal/jejunal | 102 (39.8) |
| direct endoscopic | 78 (30.5) |
| tube | 24 (9.4) |
| Rectum/colon/terminal ileum | 107 (41.8) |
| direct endoscopic | 106 (41.4) |
| enema | 1 (0.4) |
| Combinationb | 4 (1.6) |
| Capsule | 45 (17.6) |
| Patients with adverse event (%) | 19 (7.4) |
| Type of adverse event – no. (%) | |
| Nausea | 6 (2.3) |
| Fever | 3 (1.2) |
| Belching | 3 (1.2) |
| Abdominal pain | 2 (0.8) |
| Emesis | 2 (0.8) |
| Food intolerancec | 2 (0.8) |
| Aspiration pneumonia | 2 (0.8) |
| Others (retrosternal pressure, hemorrhage, pharyngeal pain, irritable bowel syndrome, loss of a tooth, polyneuropathy, weight gain,d bloody diarrhea, hypertension, increased peristaltic activity) | Each 1 (0.4) |
| No adverse events | 216 (84.4) |
a
Antibiotic induction: antibiotic given before the FMT treatment as a preparation.
b
Direct endoscopic gastric/duodenal/jejunal + direct colonoscopic.
c
1 × spinach; 1 × food intolerance not specified.
d
10 kg over 12 months after FMT (body mass index change from 25.7 to 29.4).